Magisterial Formulas: Advances in Cannabinoid Research, Product Offering and Patient Access
TORONTO, Dec. 10, 2020 (GLOBE NEWSWIRE) Avicanna Inc. (
Avicanna or the
Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces the launch of its medical cannabis program in Colombia, under compound pharmacy legislation “Formulaciones Magistrales”, in which Avicanna will provide its standardized, industry-leading cannabinoid formulary to patients and the medical community. Additionally, this program includes the education and training of the medical community and a comprehensive patient support program.
Aras Azadian, CEO of Avicanna Inc., commented: “After 2 years of preparation, we are proud to be launching this complete program in a market that is very significant to us and to be doing so with a medical community that we have been working
Magisterial Formulas: Advances in Cannabinoid Research, Product Offering and Patient Access
TORONTO, Dec. 10, 2020 (GLOBE NEWSWIRE) Avicanna Inc. (
Avicanna or the
Company) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces the launch of its medical cannabis program in Colombia, under compound pharmacy legislation Formulaciones Magistrales , in which Avicanna will provide its standardized, industry-leading cannabinoid formulary to patients and the medical community. Additionally, this program includes the education and training of the medical community and a comprehensive patient support program.
Aras Azadian, CEO of Avicanna Inc., commented: After 2 years of preparation, we are proud to be launching this complete program in a market that is very significant to us and to be doing so with a medical community that we have been working closely